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Raskaudenaikainen malariatartunta voi paitsi aiheuttaa raskaana oleville äideille oireisen malarian, 
myös johtaa kehittyvän sikiön ennenaikaiseen syntymään, pieneen syntymäpainoon, spontaaniin 
aborttiin tai kohtukuolemaan. Oireisen malarian lisäksi oireeton, usein submikroskooppinen, malaria-
parasitemia on Saharan eteläpuolisessa Afrikassa etenkin ensi kertaa raskaana olevilla naisilla 
yleisenä esiintyvä malarian muoto ja sen tiedetään liittyvän sikiön osalta samoihin seurauksiin kuin 
oireisenkin malarian. Raskaudenaikainen oireeton malaria on yleensä ns. istukkamalaria, jossa 
malarialoisioiden monistuminen tapahtuu lähinnä istukan verenkierrossa. Tästä syystä loisioita on 
vain harvoin havaittavissa perifeerisessä verenkierrossa. PCR-menetelmää hyödyntäen on kuitenkin 
mahdollista havaita pienenkin parasiittitiheyden infektiot. 
Tässä tutkimuksessa vertasimme oireettoman submikroskooppisen malaria-parasitemian yhteyttä 
raskaana olevien Malawilaisten naisten fysiologisiin ominaisuuksiin. 1320 naista osallistui 
tutkimukseen, heistä 1308 täytti tämän tutkimuksen sisäänottovaatimukset.  
Tutkimuksessa käytetty aineisto on kerätty vuosina 2003–2006 Lungwenan kylän terveyskeskuksen 
äitiyspoliklinikalta Malawissa osana LAIS-tutkimusprojektia. Osallistuneilta äideiltä otettiin 
ensimmäisen käynnin yhteydessä verinäyte, josta tunnistimme PCR-menetelmää käyttäen P. 
falciparumille spesifisen laktaattidehydrogenaasi-geenin. Malarian esiintyvyyttä verrattiin 
tutkimuskäynnillä mitattuihin fysiologisiin arvoihin ja tietoihin, joita selvitettiin kyselykaavakkeiden 
avulla.  
Malarian kokonaisesiintyvyys tutkimuspopulaatiossa oli 40,6 %. Anemiasta kärsi 48,1 % tutkituista, 
21-vuotiaita tai alle, oli 37,0 %, ensi kertaa raskaana oli 22,9 %, aliravitsemukseen viittaava MUAC 
oli 15,9 %:lla ja alipainoon viittaava BMI oli 5,0 %:lla. HIV-infektio oli tutkittu vain 12,0 %:lta 
tutkimukseen osallistuneista, joten sen yhteyttä oireettomaan infektioon ei voitu vakuuttavasti 
arvioida. 
Tutkimuksessa havaittiin, että anemia (AOR 1.5, 95 % CI 1.2 – 1.9, p<0.01), ikä (21 vuotta tai alle) 
(AOR 1.5, 95 % CI 1.1 – 2.0, p<0.01), sekä ensi kertaa raskaana oleminen (AOR 2.8, 95 % CI 1.9 – 
3.9, p<0.01), korreloivat vahvasti oireettoman malariainfektion kanssa. MUAC:illa, alipainolla tai 
varmistetulla HIV-infektiolla ei havaittu merkittävää yhteyttä malariainfektion kanssa.  
Tämän opinnäytteen alkuperäisyys on tarkastettu Turnitin OriginalityCheck-ohjelmalla Tampereen 
yliopiston laatujärjestelmän mukaisesti.  
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ABSTRACT 
 
Pregnancy associated malaria (PAM) is a serious condition not only for the developing foetus but for 
the pregnant mother too.  In most cases PAM manifests as placental malaria that does not necessarily 
give rise to symptoms usually attributed to malaria. Such infection is therefore called asymptomatic 
malaria parasitemia. PAM is also often a sub-microscopic infection, meaning that it is difficult to 
detect with light microscopy. Traditionally only women suffering from microscopically verified 
malaria have been treated. It has been recognized, however, that asymptomatic, sub-microscopic 
malaria parasitemia poses the same, if not greater, risks to the foetus as symptomatic parasitemia. 
In this thesis we studied the prevalence of asymptomatic malaria in 1320 pregnant Malawian women 
and its relation to the characteristics of the women. We collected dried blood spots (DBS) from 
peripheral venous blood from pregnant asymptomatic Malawian women in the second trimester of 
pregnancy. We then analysed the DBS samples with real-time PCR, dividing the women into 
parasitemic or non-parasitemic according to our analysis results.  
We also collected basic physiological data, including haemoglobin, weight, height, parity, HIV status 
and age. We analysed the correlations between the parasitemia status and the physiological factors.  
We found that asymptomatic malaria is more common with primigravida (Adjusted odds ratio (AOR) 
2.8, 95 % CI 1.9 – 3.9, p<0.01), young (21 year-olds or younger) (AOR 1.5, 95 % CI 1.1 – 2.0, 
p<0.01) and anaemic (AOR 1.5, 95 % CI 1.2 – 1.9, p<0.01) women. In those who were HIV positive, 
the results were inconclusive (OR 1.9, 95 % CI 0.9 – 3.9, p=0.094), as was also the case with those 
who had BMI under 18.5 kg/m2 (OR 1.3, 95 % CI 0.8 – 2.2, p=0.279) or MUAC under 23 cm (OR 
1.2, 95 % CI 0.9 – 1.6, p=0.189). 
Our results show that low parity, young age and anaemia in pregnant women are the factors that are 
most closely associated with asymptomatic malaria. Over all, the results of this study are in line with 
the results of previous studies. It appears that asymptomatic malaria in pregnant women correlates 
with physiological characteristics basically in the same way as in symptomatic malaria.  
The results of this study lead us to recommend the continuation of the present protocol of intermittent 
preventive treatment in pregnancy (IPTp). Future studies are needed to determine whether 
undernourishment and asymptomatic malaria-parasitemia are connected.  
  
3 
 
ABBREVIATIONS 
 
AOR   Adjusted odds ratio  
BMI Body Mass Index 
CI Confidence interval 
CSA Chondroitin sulphate A 
CVD Cardiovascular disease 
DBS Dried blood spot 
DNA Deoxyribonucleic acid 
HIV  Human immunodeficiency virus  
IPTp Intermittent preventive treatment in pregnancy 
IRS Indoor residual spraying 
ITN Insecticide-treated mosquito nets 
MUAC Mid upper arm circumference 
OR Odds ratio 
PAM Pregnancy associated malaria 
PCR Polymerase chain reaction 
PfEMP-1 P.falciparum erythrocyte membrane protein-1 
RDT Rapid diagnostic test 
SD Standard deviation 
SP Sulfadoxine-pyrimethamine 
STD Sexually transmitted disease 
WHO World Health Organization 
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1 INTRODUCTION  
 
In recent years, the knowledge about asymptomatic parasitemia in pregnancy associated malaria 
(PAM) has gone forward. The use of rapid diagnostic testing (RDT) and real-time PCR have revealed 
that in sub-Saharan Africa there is a significant amount of pregnant women who are having 
asymptomatic sub-microscopic malaria parasitemia. Many studies have emphasized the importance 
of asymptomatic parasitemia as an obstacle in eradicating malaria. (1–5)  
PAM is often associated with placental malaria, which is a major threat for the normal development 
of the foetus. (6) It increases the risk of premature birth, causes intrauterine growth-retardation and 
low birth weight. It also poses a risk of congenital malaria, meaning intrauterine infection of the 
foetus before or during birth. Placental malaria also attributes to maternal anaemia. (7–9) Placental 
malaria is mainly caused by Plasmodium falciparum strains expressing the VAR2CSA surface 
antigen that mediate erythrocyte sequestration in the placenta. This is especially the case in sub-
Saharan Africa, where many individuals in high transmission settings have developed partial 
immunity to other strains of P. falciparum but have not encountered this strain before. (10–12) 
It is known that PAM is more common in pregnant women who have anaemia, are first time pregnant 
(primigravida) and who are young. (6,13,14) It has not been conclusively shown previously that this 
is valid in asymptomatic women as well. The main interest of our study is to look into the relationship 
of these factors in the presence of asymptomatic malaria parasitemia in pregnancy. In addition we are 
looking into the relationship between the pregnant women nutritional status and malaria parasitemia. 
The hypothesis of our study was that anaemia, primigravida and young age are associated with 
asymptomatic parasitemia in the same way as in symptomatic parasitemia.  
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1.1 Malaria epidemiology  
 
Malaria is an infectious disease which is caused by parasites of the Plasmodium genus. The disease 
is transferred between humans by the bites of female mosquitoes belonging to the Anopheles genus. 
(15) The Anopheles genus comprises of close to 480 species of which over 100 are known to be able 
to transmit human malaria. However, only about 30 – 40 species are considered to play any important 
roles in the transmission of malaria. (15,16) 
Globally over 3.2 billion people live in areas endemic to malaria. (17) Malaria is endemic only in the 
tropical and sub-tropical areas of the Earth, and most of the infections appear in sub-Saharan Africa, 
as an estimated 88 % of all the reported cases of malaria and 90 % of all deaths caused by malaria are 
recorded there. (15) 
Malaria is one of the deadliest diseases worldwide. According to WHO, in 2015 approximately 212 
million people fell ill with malaria and an estimated 236 000 to 635 000 people died of it. (15,17) 
Malaria poses a disproportionate burden of disease especially to the poor, children under five years 
of age and pregnant women. (7) The disease threatens an estimated 25 to 125 million pregnancies 
world-wide every year (6,18) and of all the deaths caused by malaria, ranging from 219 000 to 
421 000 are children under five years of age living mostly in Africa. (15) These numbers are equal to 
one child dying every two minutes. Although malaria is not the number one cause of death for young 
children in sub-Saharan Africa anymore, it is still one of the most important factors contributing to 
child mortality that could also be almost entirely prevented. (15) 
Several species of malaria parasites have been identified but only five different Plasmodium species 
are known to have caused infection to humans. These are P. falciparum, P. vivax, P. malariae, P. 
ovale and P. knowlesii. (19) 
The most prevalent one is infection caused by Plasmodium falciparum which is to be blamed for most 
of the fatal infections. (15) Infections occurring outside of Africa are mostly due to P. vivax, as it is 
capable to develop in a wider range of temperatures. (15) 
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1.2 Life cycle of malaria parasite 
 
Malaria parasite gets transmitted to its host by mosquitoes of the Anopheles genus that act as vectors 
carrying the parasite. The parasite resides in the saliva of infected mosquitoes and gets transferred 
into its host’s subcutaneous tissue, or rarely straight to the bloodstream through mosquito bites. (20) 
At this point the parasite is called a sporozoite. It then seeks its way into the liver, where it matures 
and starts multiplying. When matured, the parasites, now called merozoites, break out of the liver and 
rush into the bloodstream. Merozoites are capable of invading red blood cells and reproducing inside 
of them. A portion of merozoites evolve into gametocytes that are immature gametes. They circle 
around in the host circulation until an unaffected mosquito bites the host and the gametocytes in the 
blood get inside the mosquitoes alimentary tract where they develop through the act of sexual 
reproduction into infectious sporozoites. They then migrate into the mosquitoes salivary glands from 
where they will pass on to a new host during the next bite. After the transmission it might take from 
one to two weeks for the symptoms of malaria to appear, sometimes even longer. (20) 
 
1.3 Disease and symptoms  
 
Malaria is generally classified into uncomplicated and severe complicated disease. (21) 
In the uncomplicated form, the typical symptoms are high cyclical fever, chills, fatigue, sweats, 
headaches, nausea and vomiting, body aches, joint pain and general malaise. (21) Clinical findings 
may include mild jaundice, enlarged spleen and/or liver, elevated temperatures and increased 
respiratory rate. (21) 
In the severe form, the disease is further complicated by organ failures leading to other more severe 
defects in the physiologic functions of the body. The manifestations include cerebral malaria, severe 
anaemia, abnormalities in blood coagulation, acute kidney failure, haemoglobinuria, hypovolaemia, 
hyperparasitemia, and hypoglycaemia. (21–23) The single most important determinant of survival is 
the emergence of metabolic acidosis (20,24) which then easily leads to development of acute 
respiratory distress syndrome. (24) The acidosis is ultimately caused by multiple factors that have the 
combined effect of reducing oxygen delivery to tissues. (25) 
If the severe condition has been going untreated for long, seizures, coma, unconsciousness and finally 
death might occur. (21) Malaria can be cured, given that it is diagnosed and treated on time and 
appropriately. (15) 
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1.3.1 Acquired immunity and asymptomatic malaria parasitemia  
 
After recovery from repeated infections, many individuals start to develop partial immunity to the 
Plasmodium parasite. That leads to each subsequent infection to give rise to fewer symptoms until at 
some point the individual might be completely asymptomatic even after being infected by malaria 
parasites. The acquired immunity develops more quickly with frequent infections. In some high 
transmission areas children might get protection against severe disease already when they are 2 – 5 
years old. After recurrent infections that would then be followed by getting totally asymptomatic in 
the early adolescence. (26) In the first couple of months after birth the new-born children are protected 
from severe infections thanks to the maternal antibodies transferred through placenta during 
pregnancy. As these maternal antibodies decrease over time, the children become more vulnerable to 
serious infections and are thus in greater danger of death during the first years of life until they reach 
a protective semi-immune status due to surviving repeated infections. (27) 
In high transmission areas it is rare for the adults to have severe symptoms from malaria infection 
and the levels of malaria parasites in the bloodstream might be so low that the infection could not be 
detected by microscopy at all. (1) 
The level of immunity is mostly determined by the number of earlier infections and person’s age. (1) 
 
1.3.2 Acquired immunity and asymptomatic parasitemia in malaria epidemiology  
 
In asymptomatic parasitemia the person carries malaria parasites in their bloodstream, but due to 
partial immunity the parasites are incapable of inducing symptoms to the affected individual. 
Nevertheless the parasitemic person could transfer the parasites to the mosquitoes biting them and 
again to other individuals. The person might then serve as a reservoir of parasites in the population, 
even though all the symptomatic persons would have been treated. (1) In areas where the transmission 
of malaria is seasonal due to the presence of wet and dry seasons and their effect to the incidence of 
Anopheles mosquitoes, this makes it possible for malaria parasites to survive through the dry season 
in the bloodstream of the asymptomatic persons. This then allows malaria infections to resume to the 
population during the wet season. (5,28–30) 
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1.4 Pregnancy associated malaria and placental malaria 
 
Pregnancy associated malaria (PAM) which often manifests as placental malaria, is a big health issue 
in sub-Saharan Africa. It represents serious health problems concerning the pregnant mother, the 
developing foetus and the new-born. (7,8) 
Complications of PAM include maternal anaemia, intrauterine growth retardation and consequent 
low birth weight, prematurity and increased perinatal mortality. (9) 
The prevalence of malaria during pregnancy has been reported to be over 50 % in some parts of sub-
Saharan Africa. (6,7) An approximated 25 to 32 million pregnancies are at risk of P. falciparum 
infection each year. (18,31) 
Malaria in pregnancy usually manifests as placental malaria and up to one fourth of all pregnant 
women in sub-Saharan Africa have evidence of placental infection at delivery. (31) Placental malaria 
is often associated with asymptomatic parasitemia and it is not unusual that it remains undetected in 
light microscopy and RDTs. (3)  
Although most individuals in high transmission areas develop partial immunity to malaria in their 
adolescence, they again become susceptible to malaria during pregnancy partly due to the 
development of a new organ, the placenta. Syncytiotrophoblasts in the placenta are abundant with 
parasite adhesion receptor, chondroitin sulphate A (CSA). (10) Although the exact mechanisms 
causing PAM are not known, it is most likely connected with the different strains of P. falciparum 
and especially the variability of their erythrocyte membrane protein-1 (PfEMP-1) that, as a variant 
surface antigen, is partly responsible for the adhesion of infected erythrocytes to the endothelial cell 
receptors in the deep organs of the body. It has been found that one variant of the PfEMP-1 protein, 
the VAR2CSA, is specific to P. falciparum strains that cause placental malaria. Only the strains of P. 
falciparum that express VAR2CSA variant of PfEMP-1 are able to cause infected erythrocytes to 
adhere in the placental CSA, so much so, that parasites expressing VAR2CSA are not able to 
sequestrate anywhere else in the body. Therefore, a pregnant mother’s immune system has never 
encountered them before and thus there is no immune response to VAR2CSA. (10,11)  
The binding of infected erythrocytes in intervillous spaces is what initiates the processes that lead to 
the pathogenesis of malaria in pregnancy. Ultimately, the sequestration of large numbers of infected 
erythrocytes piling up in the placenta impairs placental function and causes pro-inflammatory effects 
potentially leading to serious foetal outcomes. This is especially the case in first pregnancies. 
(10,11,32,33)  
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During the following pregnancies, however, anti-VAR2CSA antibodies can be found in pregnant 
women’s circulation, giving them protective immunity against these variant parasites. These 
antibodies efficiently reduce the adhesion of infected erythrocytes to syncytiotrophoblasts in the 
intervillous spaces and protect the mother and the foetus from the most severe effects of placental 
infection. The level of antibodies can be measured and it makes it possible to evaluate the level of 
immunity towards placental malaria. (11,34) It is worth mentioning that primigravidae are also able 
to produce these antibodies from the first quarter of the pregnancy after encountering VAR2CSA-
expressing parasites but not in such quantities that it would provide them sufficient protection against 
malaria. (11,35) Therefore it is likely that malaria susceptibility in primigravidae is at least partly 
related to the low levels of anti-VAR2CSA antibodies. (36)  
In addition to anti-VAR2CSA antibodies, many different biomarkers have been studied to help in the 
diagnosis of PAM but so far no biomarkers have been found to be specific, at least when used alone. 
Combinations of multiple biomarkers, however, could have some diagnostic value in identifying the 
most susceptible patients. (11,37)  
On top of other serious effects, placental malaria may also lead to congenital malaria, meaning 
infection of the foetus or the new-born either during pregnancy or during the course of the delivery. 
(7) It can be defined as having asexual malaria parasites in cord blood or peripheral blood during the 
first week of life with or without symptoms. Earlier it was thought that congenital malaria occurs 
rather rarely but according to new estimates, it is likely that almost 30 % of new-borns in moderate 
to high transmission areas may be born with having Plasmodium parasites in their bloodstream. 
(7,38–40) 
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1.5 Malaria prevention 
 
In principle, the interventions needed to prevent malaria are often cheap and relatively simple. These 
methods of prevention are practical in all kinds of populations, from children to pregnant women. 
 
1.5.1 Vector control 
 
Vector control is about preventing the mosquitoes from acquiring or passing on an infection between 
humans. The main methods for achieving this are sleeping under insecticide-treated mosquito nets 
(ITN) or spraying the indoors with long lasting insect repellents i.e. indoor residual spraying (IRS). 
(15) To be effective, a large proportion of households on an area should be sprayed. One spraying 
might guarantee protection for several months. (41)  
These are especially effective means of prevention as mosquitoes of the Anopheles genus only bite 
from dusk to dawn. In some field trials the use of ITNs has reduced the incidence of malaria by over 
50 %. (42) Similar impact has been recorded for the use of IRS, but the data is not conclusive. (43) 
Where applicable, the use of ITNs and IRS can be complemented with larval source management 
which may help reduce the amount of Anopheles mosquitoes on an area. (44,45)  
The most important factor has been the introduction of ITNs in the mid-2000s. One study found that 
full employment of ITNs in a Senegalese village of Dielmo nearly eliminated parasite carriage in the 
population. (46) 
The proportion of population in sub-Saharan Africa sleeping under ITNs has increased substantially 
from less than 2 % in 2000 to an estimated 55 % in 2015. (15) There is still work to be done though 
until 100 % of population in Africa is sleeping under ITNs.  
 
1.5.2 Chemoprevention 
 
Chemoprevention, meaning the prevention of blood stage infections by parasites in cases where 
vector control has not succeeded, consists of use of prophylactic antimalarial drugs, preventative and 
curative treatment and, hopefully in the future, anti-malarial vaccines.  
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Chemoprevention has been found to be markedly effective against malaria parasitemia in pregnant 
women and young children. (15)  
For pregnant women, the most effective means of prevention is intermittent preventive treatment in 
pregnancy (IPTp). It comprises of regular administration of sulfadoxine-pyrimethamine (SP) 
medication during pregnancy to all pregnant women. Several studies have shown that IPTp has the 
potential to affect adverse outcomes like maternal anaemia, (47) low birth weight (48) and perinatal 
mortality (49). In a study by Luntamo et al. it was found that when combining SP with azithromycin, 
the prevalence of PCR-diagnosed peripheral P. falciparum malaria at delivery was decreased 
compared to administering SP alone. (50) 
 
1.5.3 Case management 
 
Better case management means better diagnosis and treatment of patients that have already been 
infected by malaria. There are several reasons that make the proper clinical diagnosis of malaria 
problematic. For example, the clinical symptoms of malaria are shared between malaria and other 
equally severe infectious diseases, like tuberculosis, pneumonia and diarrhoea. In many places there 
are not enough well-trained health personnel to take care of the cases. There may also be a lack of 
resources, such as microscopes, RDTs or drugs. (51) Malaria parasites are also developing resistance 
to some drugs that have been widely used earlier. (52,53). Appropriate treatment of malaria is heavily 
dependent on the resistance situation of the local Plasmodium parasite strains and is subject to change 
during time.  
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2 MATERIAL AND METHODS 
 
2.1 Study objective 
 
The objective of this study was to investigate the prevalence of asymptomatic malaria in pregnant 
Malawian women and its relation to their characteristics. 
Our assumption was that asymptomatic malaria parasitemia should be more prevalent in young, 
primigravida undernourished women with anaemia as is the case with symptomatic cases of malaria. 
 
2.2 Study subjects and sample collection 
 
The samples were collected as part of the Lungwena Antenatal Intervention Study (LAIS), which is 
described in detail elsewhere (54). Briefly, a total of 1320 consenting women who presented at a rural 
antenatal clinic after 14 but before 26 completed gestation weeks were enrolled during December 
2003 and October 2006 at a single rural health center in Lungwena in the Mangochi district in 
southern Malawi. The women had to be over 15 years old, have an ongoing ultrasound confirmed 
pregnancy and had to have felt the movements of the foetus. Exclusion criteria for participation 
included known maternal tuberculosis, asthma, hypertension, CVDs, diabetes, kidney or liver disease, 
epilepsy, mental issues or any ongoing severe acute illness warranting hospital referral, twin 
pregnancy, pregnancy complications evident at enrolment visit, prior receipt of antimalarial drugs 
during pregnancy and history of serious allergic reactions to any of the drugs to be used in the study 
or other serious conditions that could act as confounding factors for the exception of HIV. (55) 
The women completed extensive forms concerning their current health and economic status and a 
complete health check-up was conducted.  
In the LAIS study, after enrolment, the study participants were divided into three randomized groups 
receiving different preventative treatment options. The women were monitored throughout the 
pregnancy and dried blood spots and other data was collected at every check-up.  
In this thesis, only data that was collected during enrolment was used. 12 participants had to be 
excluded from the study due to inconclusive PCR results. Thus, the number or participants in this 
study was 1308.  
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At enrolment visit 5 ml blood was taken from median antebrachial vein. Giemsa-stained thin and 
thick blood films were prepared and subsequently interpreted by an experienced microscopist in a 
local research laboratory. From the blood samples taken at clinic, 100 l (2 spots, each 50 l) is 
applied to Whatman FTA filter paper (Whatman plc, Maidstone, UK), air-dried and placed in 
individually sealed plastic bags with desiccant. The sample bags were stored in dry condition at room 
temperature prior to transport to the University of Tampere, Finland.  
 
2.3 DNA extraction 
 
Dried blood spots (DBS) were cut from each filter paper 3 times using 6 mm puncher and deposited 
into 96-deepwell plate. The blank filter paper was punched 4-5 times between samples to avoid 
contamination. After having punched a total of 90 samples to the 96-well plate, 1 ml of 1x PBS and 
50µl of 10 % saponin were added to each well containing DBS. The plate was then covered with a 
foil plate cover and vortexed for 20-30 seconds and left to incubate overnight at 4°C. 
The plate was then centrifuged for 1 minute at 800 rpm. The supernatant (PBS/Saponin mix) was 
aspirated and discarded from each well of the plate. 1 ml of PBS was added to each well of the plate 
containing the DBSs and the plates were covered with foil covers and vortexed for 20-30 seconds. 
The plate was left to incubate at 4°C for 30 minutes. Then the plate was again centrifuged at 800 rpm 
for 1 minute. The fluid was once again aspirated and discarded. 100 µl of sterile water was added to 
each well of the plate containing DBSs. 50µl of 20 % Chelex 100-solution was also added to each 
sample. After this, the plates were once again covered with foil plate covers and then put into 95-
99°C water bath for 12 minutes. The plates were vortexed every 2-3 minutes. The plates were then 
centrifuged at 1500 rpm for 5 minutes.  
After that as much liquid as possible was transferred from the wells to a new 96-deepwell plate.  
The new plate was centrifuged for 10 minutes at 1500 rpm. Then the final white to yellowish 
supernatant was transferred to the final 0.2 ml 96-well plate, avoiding the Chelex beads in the bottom 
of the wells. This supernatant now contained all the extracted DNA from the DBS. The plate was 
then covered with foil cover, centrifuged at 1500 rpm for 1 minute, labelled and stored at -20°C.  
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2.4 Real-time PCR 
 
All gDNA samples from DBS were amplified in an assay targeting the Plasmodium falciparum lactate 
dehydrogenase gene (LDH). The primers and probe sequences are as follows: Forward primer - ACG 
ATT TGG CTG GAG CAG AT; reverse primer - TCT CTA TTC CAT TCT TTG TCA CTC TTT 
C; probe - FAM-AGT AAT AGT AAC AGC TGG ATT TAC CAA GGC CCC A-TAMRA. Reaction 
volumes were 25 µl each, consisting of 12.5 µl Universal TaqMan Master mix (Applied Biosystems), 
2 µl of DNA, 1.25 µl LDH forward primer (20 µM), 1.25 µl LDH reverse primer (20µM), 0.25µl 
LDH probe (20µM) and molecular grade water.  
All reactions were run in duplicate on an ABI 7900 Real-Time System (Applied Biosystems, Foster 
City, CA, USA). The cycling conditions were: 50C for 2 min, 95C for 10 min, and 45 cycles of 
95C for 15 s followed by 60C for 1 min. Each reaction plate included four serial dilutions (10, 1, 
0.1, 0.01 ng/µl) of Plasmodium falciparum 3D7 genomic DNA as positive controls and a negative 
control with molecular-grade water in place of DNA. Samples were considered positive if both 
amplification curves reached the threshold line. Reactions with only one amplification curve reaching 
the threshold line were repeated for a third time.  
 
2.5 Statistical analysis 
 
We used STATA 13.1 –statistics and data analysing program for the analytics. We used Microsoft 
Excel 2013 for various data editing purposes.  
The variables used were haemoglobin, age, parity, BMI, MUAC and HIV-status. These variables 
were then compared against the parasitemia status, defined as positive result in real time PCR. The 
value of the parasitemia status, 0 or 1, was incorporated into the data set that comprised of all the 
other variables.  
In our analysis, we only used the results of the PCR to determine whether the study subject is 
parasitemic or not, 1308 of the 1320 study participants had a valid PCR result. 
STATA was then used to calculate new values like BMI or for grading the study subjects according 
to differences in their characteristics, e.g. grading subjects to anaemic or not according to their 
respective haemoglobin levels. STATA was also used to calculate uni- and multivariate logistic 
regression, chi2 –tests and other relevant tests.  
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Correlation between physiological variables and the prevalence of asymptomatic malaria parasitemia 
were tested for significance using univariate logistic regression separately for each variable. To 
calculate adjusted odd ratios (AOR), bivariate logistic regression was used, including the variables 
with p-value <0.05. Therefore the variables used to calculate AORs were age, parity and 
haemoglobin.  Parasitemia status, determined by PCR result, was used as the dependent variable. 
AOR were calculated with 95 % confidence intervals. P-values less than 0.05 were considered 
statistically significant. 
In determining how to categorize the variables, we used cut-offs that are widely accepted as 
physiologically significant.  
For the definition for anaemia during pregnancy, we used WHOs definition of haemoglobin under 
110 g/l as the cut-off, dividing the study participants into two groups, to those whose haemoglobin 
was under 110 g/l and those whose haemoglobin was 110 g/l or over (56) 
For age, there was not any strong evidence that would have suggested to choose any one definite cut-
off point as age seems to correlate with parasitemia rather linearly. However, most studies found the 
most significant correlation when age was under 18 – 25 years. (13,57–59) We decided to divide the 
women in our study into two groups, those of age 21 or under and those of over age 21. (13) 
For parity, we divided the participants into primigravida and multigravida women as it has been found 
in previous studies that the biggest difference in malaria prevalence is between primigravida and 
multigravida. (6,13,60) 
For BMI, we divided the women according to BMI under 18.5 kg/m2 or to BMI 18.5 kg/m2 or over 
according to guidelines for undernourishment by WHO. (61)  
For MUAC (Mid Upper Arm Circumference), we would have used 18.5 cm as a cut-off for 
malnutrition, as that has been suggested by several sources. (62) However, the lowest measured 
MUAC in our study population was 19.1 cm, which is considered normal. Some studies recommend 
a more conservative cut-off of 23 cm for pregnant women, which we also used in this study. (63,64) 
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3 RESULTS 
 
3.1 Characteristics of study participants 
 
The characteristics of study participants are summarized in table 1.  
The mean age of the participants was 24.9 years with a standard deviation of 6.4 years. Youngest 
study participant was 15 years old and oldest was 49 years old. BMI values varied from severe 
undernutrition of 12.8 kg/m2 to moderate obesity of 33.9 kg/m2. The mean for BMI was 21.8 kg/m2 
(SD 2.2). The mean for MUAC (Mid Upper Arm Circumference) was 25.2 cm (SD 2.0), lowest 
MUAC being 19.1 cm and highest 39.6 cm. Number of pregnancies varied from 1 to 10. The mean 
for parity was 3.3 (SD 2.0). Haemoglobin levels varied from levels indicating severe anaemia of 50 
g/l to high levels of 173 g/l. The mean haemoglobin in the study population was 110.2 g/l (SD 18.7). 
 
Table 1 - Study subjects and their characteristics 
 
Characteristic (N)  All participants Parasitemic Non-parasitemic 
  
n=531 n=777 
Age (years) (1308) 
   
Mean (SD) 24.9 (6.4) 23.1 (6.0) 26.1 (6.4) 
BMI (kg/m2) (1307) 
   
Mean (SD) 21.8 (2.2) 21.6 (2.1) 21.9 (2.2) 
Parity (pregnancies) (1308) 
  
Mean (SD) 3.3 (2.0) 2.7 (1.8) 3.8 (2.0) 
Haemoglobin (g/l) (1308) 
  
Mean (SD) 110.2 (18.7) 107.2 (18.7) 112.3 (18.4) 
MUAC (cm) (1308) 
   
Mean (SD) 25.2 (2.0) 25.0 (1.9) 25.4 (2.2) 
N = total number 
SD = standard deviation 
n = number 
BMI= body mass index 
MUAC = mid upper arm circumference  
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3.2 Prevalence of asymptomatic P. falciparum malaria 
  
In this study we analysed a total of 1307 blood samples with light microscopy and 1308 DBS samples 
with PCR. The prevalence of malaria according to microscopy and PCR, is summarized in table 2.  
Of the 1307 participants, microscopic malaria was found in 116 and 1191 were considered non-
parasitemic. Of those 116 microscopic malaria findings, 95 were interpreted to be P. falciparum and 
21 were interpreted as P. malariae. PCR revealed a total of 531 positive malaria results. That left us 
with 777 women who did not have malaria parasitemia at the time of enrolment. Thus, the incidence 
of asymptomatic malaria parasitemia in our data was 40.6 % (95 % CI 37.9 - 43.3) and 8.9 % (95 % 
CI 7.3 - 10.4) according to real time PCR and light microscopy, respectively. All of the participants 
were asymptomatic at the time and they had not had any anti-malarial drugs before enrolling to the 
study.  
 
Table 2 - Prevalence of malaria according to light microscopy and PCR 
Parasites (N) n (%) 95 % CI 
Microscopic parasitemia (1307) 
  
Negative  1191 (91.1) [89.6 - 92.7] 
Positive 116 (8.9) [7.3 - 10.4] 
Parasite type (116) 
  
P. falciparum 95 (81.9) [74.9 – 88.9] 
P. malariae 21 (18.1) [11.6 - 26.3] 
PCR Result (1308) 
  
Negative  777 (59.4) [56.7 - 62.1] 
Positive 531 (40.6) [37.9 - 43.3] 
N = total number 
n = number 
% = percentage 
CI = confidence interval 
PCR = polymerase chain reaction   
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3.3 Factors potentially affecting the prevalence of asymptomatic malaria 
The physiological parameters potentially affecting the prevalence of asymptomatic malaria 
parasitemia are categorized in table 3.  
One third, or 37.0 % (95 % CI 34.4 – 39.6) of the study population were 21 year old or under. Only 
5.0 % (95 % CI 3.9 - 6.2) were found to be underweight, defined as BMI under 18.5 kg/m2.  About 
22.9 % (95 % CI 20.6 - 25.1) of the women were primigravida. Almost half, or 48.1 % (95 % CI 45.4 
- 50.8) of the study participants were anaemic at enrolment.  Mid upper arm circumference (MUAC) 
was 23 cm or under in 15.9 % (95 % CI 13.9 - 17.9) of the study population. HIV was tested only 
from 157 study participants, of whom 70.7 % (95 % CI 63.6 - 77.8) were found to be HIV positive.  
 
 
Table 3 - Physiological factors potentially affecting parasitemia prevalence 
Characteristic (N) n % [95% CI] 
Age (years) (1308) 
  
≤21 484 37.0 [34.4 - 39.6] 
>21 824 63.0 [60.4 - 65.6] 
BMI (kg/m2) (1307) 
  
<18.5 66 5.0 [3.9 - 6.2] 
≥18.5 1241 95 [93.8 -96.1] 
Parity (1308) 
  
Primigravida 299 22.9 [20.6 - 25.1] 
Multigravida 1009 77.1 [74.9 - 79.4] 
Haemoglobin (g/l) (1308) 
  
<110 629 48.1 [45.4 - 50.8] 
≥110 679 51.9 [49.2 - 54.6] 
MUAC (cm) (1308) 
  
≤23 208 15.9 [13.9 - 17.9] 
>23 1100 84.1 [82.1 - 86.1] 
HIV-status (157) 
  
Positive 111 70.7 [63.6 - 77.8] 
Negative 46 29.3 [22.2 -36.4] 
N = total number 
n = number 
% = percentage 
MUAC = mid upper arm circumference 
CI = confidence interval 
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3.4 Women’s characteristics associated with asymptomatic malaria 
 
We found that asymptomatic malaria parasitemia is strongly associated with anaemia, primigravity 
and age of 21 years and under (Table 4). We found a small correlation between malaria parasitemia 
and BMI under 18.5 kg/m2, MUAC under 23 cm and positive HIV-status but the findings were not 
statistically significant. Additional figures can be found from the appendix.  
Women who had anaemia were 1.5 times more likely to be parasitemic compared to the non-anaemic 
(AOR 1.5, 95% CI 1.2 – 1.9, p<0.01) (Table 4) (Figure 1, Appendix).  
Women who were 21 years old or under were 1.5 times more likely to have parasitemia compared to 
their older counterparts (AOR 1.5, 95 % CI 1.1 - 2.0, p<0.01) (Figure 2, Appendix). 
We found asymptomatic malaria to be more common in primigravida compared to multigravida 
women. Women who were pregnant for the first time had parasitemia incidence of 65.6 % compared 
to the 33.2 % in the women who were pregnant for at least the second time. Odds for parasitemia in 
primigravida women were 2.8 times higher. (AOR 2.8, 95 % CI 1.9 – 3.9, p<0.01) (Figure 3, 
Appendix) 
We found a small correlation between low MUAC (Mid Upper Arm Circumference) and parasitemia 
status, but it was not large enough to be concerned significant. (OR 1.2, 95% CI 0.9 – 1.6, p=0.189) 
(Figure 4, Appendix). 
It also seemed that parasitemia is slightly more common in the presence of BMI under 18.5, but the 
results were not statistically significant (OR 1.3, 95% CI 0.8 – 2.2 p=0.279) (Figure 5, Appendix). 
Positive HIV status also seemed to predict higher prevalence of P. falciparum parasitemia, but due to 
the low number of study participants tested for HIV, the results were not statistically significant. (OR 
1.9, 95 % CI 0.9 – 3.9, p=0.094) (Figure 6, Appendix). 
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Table 4 - Women’s characteristics associated with prevalence of asymptomatic sub-
microscopic malaria 
Physiological factor Prevalence of P. falciparum % (n/N) OR [95 % CI] AOR [95 % CI] p 
Age  
  
 
 
≤21 years 55.2 (267/484)  2.6 [2.1 - 3.3] 1.5 [1.1 – 2.0] <0.01 
>21 years  32.0 (264/824) 1 1 
 
BMI  
  
 
 
<18.5 (kg/m2) 47.0 (31/66) 1.3 [0.8 - 2.2]  0.279 
≥18.5 (kg/m2) 40.2 (499/1241) 1  
 
Parity 
  
 
 
Primigravida 65.6 (196/299) 3.8 [2.9 - 5.0] 2.8 [1.9 – 3.9] <0.01 
Multigravida 33.2 (335/1009) 1 1 
 
Haemoglobin  
  
 
 
<110 g/l 46.4 (292/629) 1.6 [1.3 - 2.0] 1.5 [1.2 – 1.9] <0.01 
≥110 g/l 35.2 (239/679) 1 1 
 
MUAC  
  
 
 
≤23 cm 44.7 (93/208) 1.2 [0.9 - 1.6]  0.189 
>23 cm 39.8 (438/1100) 1  
 
HIV-status 
  
 
 
Positive 42.3 (47/111) 1.9 [0.9 - 3.9]  0.094 
Negative 28.3 (13/46) 1  
 
N = total number 
% = percentage 
n = number of positive P. falciparum 
OR = odds ratio 
AOR = adjusted odds ratio 
CI = confidence interval 
p-value is considered significant when <0.05 
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4 DISCUSSION 
 
We found that primigravida, young, anaemic women are more susceptible to having asymptomatic 
malaria parasitemia during pregnancy compared to their counterparts. The results of this study are in 
line with previous studies (3,6,65,66). According to our results, age, parity and haemoglobin are the 
factors that are most closely associated with asymptomatic malaria. Our results are also in line with 
previous studies, in which age, parity and anaemia were correlated with symptomatic malaria. 
(13,60,65) 
Although it would be plausible to think that age and parity are linked to each other and are in fact 
confounding factors to each other, it has been proven in previous studies that they actually act as 
individual variables on their own (13,57). This was now also proven in our study, as adjusted odd 
ratios were significant for both age and parity, when using age as adjusting factor for parity and vice 
versa.  
Originally, we were supposed to also assess the correlation between nutritional status and parasitemia 
status. However, the lack of information over the participants’ pre-pregnancy BMI and the lack of 
undernourished participants in general made it difficult to evaluate the significance of these factors. 
Despite these setbacks, there was a slight correlation between undernourishment and parasitemia 
according to MUAC and regular BMI at enrolment. For determining whether undernourishment in 
pregnant women and asymptomatic malaria-parasitemia are connected, future research is needed.  
The analysis in our study was based on the fact that Plasmodia parasites can be detected in blood 
samples via molecular diagnostics in addition to traditional microscopy. Molecular methods are 
considered to be more sensitive in detecting malaria parasites, compared to microscopy. (67) 
Our study did not necessarily bring any new information on the subject, but as we used sensitive 
molecular diagnostic methods, it helps to confirm the results obtained in previous studies. Most of 
the other studies conducted found these correlations using rapid diagnostic testing or microscopy. As 
PCR is able to detect even the slightest amounts of malaria parasites in circulation, our results help 
to confirm that even very low parasite densities correlate with anaemia, parity and age.  
However, as the prevalence of malaria is relatively high in the common population regardless of these 
factors, it is difficult to propose any definite rules when preventive treatment should be commenced. 
Likewise, no one should be left untreated if their characteristics should lead us to assume that the 
probability of asymptomatic infection is unlikely.  
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Therefore, the results of this study lead us to recommend the continuation of the present protocol of 
intermittent preventive treatment in pregnancy (IPTp), possibly coupled with azithromycin. As the 
prevalence of PAM is slightly greater in young and primigravida women, it would be important to 
target especially these groups. Other means of prevention that should be promoted are the use of 
insecticide treated bed nets and indoor residual spraying. In symptomatic cases, better case 
management is important. In the future, if vaccines for malaria are to become more effective, their 
use should be heavily promoted so that the burden of disease caused by malaria could be profoundly 
diminished and malaria could eventually be completely eradicated. 
 
  
24 
 
5 REFERENCES 
 
1.  Lindblade KA, Steinhardt L, Samuels A, Kachur SP, Slutsker L. The silent threat: asymptomatic 
parasitemia and malaria transmission. Expert Rev Anti Infect Ther. 2013 Jun;11(6):623–39.  
2.  Laishram DD, Sutton PL, Nanda N, Sharma VL, Sobti RC, Carlton JM, et al. The complexities of 
malaria disease manifestations with a focus on asymptomatic malaria. Malar J. 2012;11:29.  
3.  Cohee LM, Kalilani-Phiri L, Boudova S, Joshi S, Mukadam R, Seydel KB, et al. Submicroscopic 
malaria infection during pregnancy and the impact of intermittent preventive treatment. Malar J. 
2014;13(1):1.  
4.  Okell LC, Ghani AC, Lyons E, Drakeley CJ. Submicroscopic Infection in Plasmodium falciparum –
Endemic Populations: A Systematic Review and Meta‐Analysis. J Infect Dis. 2009 Nov 
15;200(10):1509–17.  
5.  Bousema T, Okell L, Felger I, Drakeley C. Asymptomatic malaria infections: detectability, 
transmissibility and public health relevance. Nat Rev Microbiol. 2014;12(12):833–840.  
6.  Desai M, Kuile FO ter, Nosten F, McGready R, Asamoa K, Brabin B, et al. Epidemiology and burden of 
malaria in pregnancy. Lancet Infect Dis. 2007 Feb 1;7(2):93–104.  
7.  Hartman TK, Rogerson SJ, Fischer PR. The impact of maternal malaria on newborns. Ann Trop 
Paediatr. 2010 Dec;30(4):271–82.  
8.  Soma-Pillay P, Macdonald AP. Malaria in pregnancy. Obstet Med. 2012 Mar 1;5(1):2–5.  
9.  McGregor IA, Wilson ME, Billewicz WZ. Malaria infection of the placenta in The Gambia, West 
Africa; its incidence and relationship to stillbirth, birthweight and placental weight. Trans R Soc Trop 
Med Hyg. 1983 Jan 1;77(2):232–44.  
10.  Fried M, Duffy PE. Adherence of Plasmodium falciparum to chondroitin sulfate A in the human 
placenta. Science. 1996;272(5267):1502.  
11.  Gueneuc A, Deloron P, Bertin GI. Usefulness of a biomarker to identify placental dysfunction in the 
context of malaria. Malar J [Internet]. 2017 Dec [cited 2017 Nov 9];16(1). Available from: 
http://malariajournal.biomedcentral.com/articles/10.1186/s12936-016-1664-0 
12.  Rogerson SJ, Hviid L, Duffy PE, Leke RF, Taylor DW. Malaria in pregnancy: pathogenesis and 
immunity. Lancet Infect Dis. 2007;7(2):105–117.  
13.  Nnaji GA, Okafor CI, Ikechebelu JI. An evaluation of the effect of parity and age on malaria 
parasitaemia in pregnancy. J Obstet Gynaecol. 2006 Jan;26(8):755–8.  
14.  Uneke CJ. Diagnosis of Plasmoduim falciparum malaria in pregnancy in sub-Saharan Africa: the 
challenges and public health implications. Parasitol Res. 2008 Feb;102(3):333–42.  
15.  WHO | World Malaria Report 2015 [Internet]. WHO. [cited 2016 Mar 7]. Available from: 
http://www.who.int/malaria/publications/world-malaria-report-2015/report/en/ 
16.  Culicidae Classification | Mosquito Taxonomic Inventory [Internet]. [cited 2017 Nov 21]. Available 
from: http://mosquito-taxonomic-inventory.info/simpletaxonomy/term/6047 
17.  Prevention C-C for DC and. CDC - Malaria - About Malaria - Facts [Internet]. [cited 2016 Oct 15]. 
Available from: http://www.cdc.gov/malaria/about/facts.html 
25 
 
18.  Dellicour S, Tatem AJ, Guerra CA, Snow RW, ter Kuile FO. Quantifying the Number of Pregnancies at 
Risk of Malaria in 2007: A Demographic Study. Fisk NM, editor. PLoS Med. 2010 Jan 
26;7(1):e1000221.  
19.  WHO | Malaria [Internet]. 2014 [cited 2017 Dec 21]. Available from: 
https://web.archive.org/web/20140903002027/http://www.who.int/mediacentre/factsheets/fs094/en/ 
20.  Miller LH, Baruch DI, Marsh K, Doumbo OK. The pathogenic basis of malaria. Nature. 
2002;415(6872):673–679.  
21.  Prevention C-C for DC and. CDC - Malaria - About Malaria - Disease [Internet]. [cited 2016 Oct 15]. 
Available from: http://www.cdc.gov/malaria/about/disease.html 
22.  Newton C, Warn PA, Winstanley PA, Peshu N, Snow RW, Pasvol G, et al. Severe anaemia in children 
living in a malaria endemic area of Kenya. Trop Med Int Health. 1997;2(2):165–178.  
23.  English MC, Waruiru C, Lightowler C, Murphy SA, Kirigha G, Marsh K. Hyponatraemia and 
dehydration in severe malaria. Arch Dis Child. 1996;74(3):201–205.  
24.  Taylor TE, Borgstein A, Molyneux ME. Acid-base status in paediatric Plasmodium falciparum malaria. 
Q J Med. 1993 Feb;86(2):99–109.  
25.  English M, Sauerwein R, Waruiru C, Mosobo M, Obiero J, Lowe B, et al. Acidosis in severe childhood 
malaria. Qjm. 1997;90(4):263–270.  
26.  Filipe JAN, Riley EM, Drakeley CJ, Sutherland CJ, Ghani AC. Determination of the Processes Driving 
the Acquisition of Immunity to Malaria Using a Mathematical Transmission Model. PLoS Comput Biol. 
2007;3(12):e255.  
27.  Prevention C-C for DC and. CDC - Malaria - About Malaria - Biology - Human Factors and Malaria 
[Internet]. [cited 2016 Dec 10]. Available from: 
http://www.cdc.gov/malaria/about/biology/human_factors.html 
28.  Churcher TS, Bousema T, Walker M, Drakeley C, Schneider P, Ouédraogo AL, et al. Predicting 
mosquito infection from Plasmodium falciparum gametocyte density and estimating the reservoir of 
infection. Elife. 2013;2:e00626.  
29.  Babiker HA, Abdel-Muhsin AM, Ranford-Cartwright LC, Satti G, Walliker D. Characteristics of 
Plasmodium falciparum parasites that survive the lengthy dry season in eastern Sudan where malaria 
transmission is markedly seasonal. Am J Trop Med Hyg. 1998;59(4):582–590.  
30.  Smith DL, McKenzie FE, Snow RW, Hay SI. Revisiting the Basic Reproductive Number for Malaria 
and Its Implications for Malaria Control. Grenfell BT, editor. PLoS Biol. 2007 Feb 20;5(3):e42.  
31.  Desai M, ter Kuile FO, Nosten F, McGready R, Asamoa K, Brabin B, et al. Epidemiology and burden of 
malaria in pregnancy. Lancet Infect Dis. 2007 Feb;7(2):93–104.  
32.  Rota C, Carles D, Schaeffer V, Guyon F, Saura R, Horovitz J. Perinatal prognosis of pregnancies 
complicated by placental chronic intervillitis. J Gynécologie Obstétrique Biol Reprod. 2006 Dec 
1;35:711–9.  
33.  Hviid L. The immuno‐epidemiology of pregnancy‐associated Plasmodium falciparum malaria: a variant 
surface antigen‐specific perspective. Parasite Immunol. 2004 Nov 1;26(11‐12):477–86.  
34.  Tutterrow YL, Salanti A, Avril M, Smith JD, Pagano IS, Ako S, et al. High Avidity Antibodies to Full-
Length VAR2CSA Correlate with Absence of Placental Malaria. Schallig HDFH, editor. PLoS ONE. 
2012 Jun 26;7(6):e40049.  
26 
 
35.  Fievet N, Le Hesran JY, Cottrell G, Doucoure S, Diouf I, Ndiaye JL, et al. Acquisition of antibodies to 
variant antigens on the surface of Plasmodium falciparum-infected erythrocytes during pregnancy. Infect 
Genet Evol. 2006 Nov;6(6):459–63.  
36.  Fried M, Nosten F, Brockman A, Brabin BJ, Duffy PE. Maternal antibodies block malaria. Nature. 
1998;395(6705):851–852.  
37.  Ruizendaal E, van Leeuwen E, Mens PF. Peripheral and placental biomarkers in women with placental 
malaria: a systematic review. Biomark Med. 2015 Mar;9(3):217–39.  
38.  Fischer PR. Congenital malaria: an African survey. Clin Pediatr (Phila). 1997 Jul;36(7):411–3.  
39.  Ndyomugyenyi R, Magnussen P. Chloroquine prophylaxis, iron/folic-acid supplementation or case 
management of malaria attacks in primigravidae in western Uganda: effects on congenital malaria and 
infant haemoglobin concentrations. Ann Trop Med Parasitol. 2000 Dec;94(8):759-768; discussion 769-
770.  
40.  Nyirjesy P, Kavasya T, Axelrod P, Fischer PR. Malaria during pregnancy: neonatal morbidity and 
mortality and the efficacy of chloroquine chemoprophylaxis. Clin Infect Dis Off Publ Infect Dis Soc 
Am. 1993 Jan;16(1):127–32.  
41.  Prevention C-C for DC and. CDC - Malaria - Malaria Worldwide - How Can Malaria Cases and Deaths 
Be Reduced? - Indoor Residual Spraying [Internet]. [cited 2016 Oct 15]. Available from: 
https://www.cdc.gov/malaria/malaria_worldwide/reduction/irs.html 
42.  Lengeler C. Insecticide-treated bed nets and curtains for preventing malaria. In: The Cochrane 
Collaboration, editor. Cochrane Database of Systematic Reviews [Internet]. Chichester, UK: John Wiley 
& Sons, Ltd; 2004 [cited 2016 Oct 15]. Available from: 
http://doi.wiley.com/10.1002/14651858.CD000363.pub2 
43.  Pluess B, Tanser FC, Lengeler C, Sharp BL. Indoor residual spraying for preventing malaria. [Review] 
[163 refs]. Cochrane Database Syst Rev. 2010;  
44.  Landoh ED, Tchamdja P, Saka B, Tint KS, Gitta SN, Wasswa P, et al. Morbidity and mortality due to 
malaria in Est Mono district, Togo, from 2005 to 2010: a times series analysis. Malar J. 2012;  
45.  Larval source management: a supplementary measure for malaria vector control: an operational manual. 
Geneva: World Health Organization; 2013.  
46.  Trape J-F, Tall A, Sokhna C, Ly AB, Diagne N, Ndiath O, et al. The rise and fall of malaria in a west 
African rural community, Dielmo, Senegal, from 1990 to 2012: a 22 year longitudinal study. Lancet 
Infect Dis. 2014;14(6):476–488.  
47.  Radeva-Petrova D, Kayentao K, ter Kuile FO, Sinclair D, Garner P. Drugs for preventing malaria in 
pregnant women in endemic areas: any drug regimen versus placebo or no treatment. In: The Cochrane 
Collaboration, editor. Cochrane Database of Systematic Reviews [Internet]. Chichester, UK: John Wiley 
& Sons, Ltd; 2014 [cited 2016 Oct 15]. Available from: 
http://doi.wiley.com/10.1002/14651858.CD000169.pub3 
48.  Kayentao K, Garner P, Maria van Eijk A, Naidoo I, Roper C, Mulokozi A, et al. Intermittent Preventive 
Therapy for Malaria During Pregnancy Using 2 vs 3 or More Doses of Sulfadoxine-Pyrimethamine and 
Risk of Low Birth Weight in Africa: Systematic Review and Meta-analysis. JAMA. 2013 Feb 
13;309(6):594.  
49.  Garner P, Gülmezoglu AM. Drugs for preventing malaria-related illness in pregnant women and death in 
the newborn. Cochrane Database Syst Rev. 2003;(1):CD000169.  
27 
 
50.  Luntamo M, Rantala A-M, Meshnick SR, Cheung YB, Kulmala T, Maleta K, et al. The Effect of 
Monthly Sulfadoxine-Pyrimethamine, Alone or with Azithromycin, on PCR-Diagnosed Malaria at 
Delivery: A Randomized Controlled Trial. Gosling RD, editor. PLoS ONE. 2012 Jul 19;7(7):e41123.  
51.  Prevention C-C for DC and. CDC - Malaria - Malaria Worldwide - How Can Malaria Cases and Deaths 
Be Reduced? - Diagnosis and Treatment [Internet]. [cited 2016 Nov 17]. Available from: 
https://www.cdc.gov/malaria/malaria_worldwide/reduction/dx_tx.html 
52.  WHO | Update on artemisinin resistance ‐ January 2014 [Internet]. WHO. [cited 2016 Nov 17]. 
Available from: http://www.who.int/malaria/publications/atoz/update-artemisinin-resistance-jan2014/en/ 
53.  Prevention C-C for DC and. CDC - Malaria - Malaria Worldwide - How Can Malaria Cases and Deaths 
Be Reduced? - Drug resistance in the Malaria Endemic World [Internet]. [cited 2016 Nov 17]. Available 
from: https://www.cdc.gov/malaria/malaria_worldwide/reduction/drug_resistance.html 
54.  Luntamo M, Kulmala T, Mbewe B, Cheung YB, Maleta K, Ashorn P. Effect of Repeated Treatment of 
Pregnant Women with Sulfadoxine-Pyrimethamine and Azithromycin on Preterm Delivery in Malawi: A 
Randomized Controlled Trial. Am J Trop Med Hyg. 2010 Dec 6;83(6):1212–20.  
55.  LAIS research plan 2006.  
56.  Organization WH, others. Iron deficiency anaemia: assessment, prevention and control: a guide for 
programme managers. 2001 [cited 2016 Oct 22]; Available from: 
http://apps.who.int/iris/handle/10665/66914 
57.  Walker-Abbey A, Djokam RR, Eno A, Leke RF, Titanji VP, Fogako J, et al. Malaria in pregnant 
Cameroonian women: the effect of age and gravidity on submicroscopic and mixed-species infections 
and multiple parasite genotypes. Am J Trop Med Hyg. 2005;72(3):229–235.  
58.  Tandu-Umba B, Mbangama AM. Association of maternal anemia with other risk factors in occurrence 
of Great obstetrical syndromes at university clinics, Kinshasa, DR Congo. BMC Pregnancy Childbirth 
[Internet]. 2015 Dec [cited 2017 Nov 20];15(1). Available from: 
http://bmcpregnancychildbirth.biomedcentral.com/articles/10.1186/s12884-015-0623-z 
59.  Tako EA, Zhou A, Lohoue J, Leke R, Taylor DW, Leke RF. Risk factors for placental malaria and its 
effect on pregnancy outcome in Yaounde, Cameroon. Am J Trop Med Hyg. 2005;72(3):236–242.  
60.  Nega D, Dana D, Tefera T, Eshetu T. Prevalence and Predictors of Asymptomatic Malaria Parasitemia 
among Pregnant Women in the Rural Surroundings of Arbaminch Town, South Ethiopia. PLoS ONE 
[Internet]. 2015 Apr 7 [cited 2016 Mar 19];10(4). Available from: 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4388389/ 
61.  WHO :: Global Database on Body Mass Index [Internet]. [cited 2016 Dec 10]. Available from: 
http://apps.who.int/bmi/index.jsp?introPage=intro_3.html 
62.  Collins S. Using Middle Upper Arm Circumference to Assess Severe Adult Malnutrition During 
Famine. JAMA. 1996 Aug 7;276(5):391–5.  
63.  Tang AM, Dong K, Deitchler M, Chung M, Maalouf-Manasseh Z, Tumilowicz A, et al. Use of cutoffs 
for mid-upper arm circumference (MUAC) as an indicator or predictor of nutritional and health-related 
outcomes in adolescents and adults: A systematic review. 2013 [cited 2016 Dec 10]; Available from: 
http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.652.8324 
64.  Ververs M, Antierens A, Sackl A, Staderini N, Captier V. Which Anthropometric Indicators Identify a 
Pregnant Woman as Acutely Malnourished and Predict Adverse Birth Outcomes in the Humanitarian 
Context? PLoS Curr [Internet]. 2013 Jun 7 [cited 2016 Dec 10];5. Available from: 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3682760/ 
28 
 
65.  Matangila JR, Lufuluabo J, Ibalanky AL, Inocencio da Luz RA, Lutumba P, Van Geertruyden J-P. 
Asymptomatic Plasmodium falciparum infection is associated with anaemia in pregnancy and can be 
more cost-effectively detected by rapid diagnostic test than by microscopy in Kinshasa, Democratic 
Republic of the Congo. Malar J. 2014;  
66.  Mayor A, Moro L, Aguilar R, Bardají A, Cisteró P, Serra-Casas E, et al. How Hidden Can Malaria Be in 
Pregnant Women? Diagnosis by Microscopy, Placental Histology, Polymerase Chain Reaction and 
Detection of Histidine-Rich Protein 2 in Plasma. Clin Infect Dis. 2012 Jun 1;54(11):1561–8.  
67.  Rantala A-M, Taylor SM, Trottman PA, Luntamo M, Mbewe B, Maleta K, et al. Comparison of real-
time PCR and microscopy for malaria parasite detection in Malawian pregnant women. Malar J. 
2010;9(1):1.  
 
  
29 
 
0,00%
10,00%
20,00%
30,00%
40,00%
50,00%
60,00%
70,00%
80,00%
≤21 >21 Total
O
F
 T
O
T
A
L
AGE
Parasitemia status and age
Positive Negative
0,00%
10,00%
20,00%
30,00%
40,00%
50,00%
60,00%
70,00%
<110 g/l ≥110 g/l Total
%
 O
F 
TO
TA
L
HAEMOGLOBIN
Parasitemia status & haemoglobin
Positive Negative
0,00%
10,00%
20,00%
30,00%
40,00%
50,00%
60,00%
70,00%
<110 g/l ≥110 g/l Total
%
 O
F 
TO
TA
L
HAEMOGLOBIN
Parasitemia status & haemoglobin
Positive Negative
APPENDIX 
 
Figure 1 
0,00%
10,00%
20,00%
30,00
40,00%
50,00
60,00%
70,00
<110 g/l ≥110 g/l Total
O
F
 T
O
T
A
L
HAEMOGLOBIN
Parasitemia status and haemoglobin
Negative
Figure 2 
30 
 
0,000 %
10,000 %
20,000 %
30,000 %
40,000 %
50,000 %
60,000 %
70,000 %
≤23 cm >23 cm Total
O
F
 T
O
T
A
L
MUAC
Parasitemia status and MUAC
Positive Negative
Figure 4 
 
 
Figure 3 
 
 
0,00%
10,00%
20,00%
30,00%
40,00%
50,00%
60,00%
70,00%
80,00%
Primigravida Multigravida Total
O
F
 T
O
T
A
L
PARITY
Parasitemia status and parity
Positive Negative
31 
 
0,00%
10,00%
20,00%
30,00%
40,00%
50,00%
60,00%
70,00%
80,00%
HIV Negative HIV Positive Total
O
F
  
T
O
T
A
L
Parasitemia status and HIV
Malaria positive Malaria negative
Figure 6 
 
Figure 5 
  
0,00%
10,00%
20,00%
30,00%
40,00%
50,00%
60,00%
70,00%
<18.5 ≥18.5 Total
O
F
 T
O
T
A
L
BMI
Parasitemia status and BMI
Positive Negative
